Files and links (2)
Published VersionCC BY-NC-ND V4.0, Open Access
Published VersionCC BY-NC-ND V4.0, Open
Journal article
The Lower-Risk Cannabis Use Guidelines (LRCUG): A ready-made targeted prevention tool for cannabis in New Zealand
Public Health in Practice, Vol.1, pp.1-4
2020
PMID: 36101675
Abstract
Cannabis use is common, especially among young people, and associated with risks for select acute and chronic adverse health and social outcomes. New Zealand features overall high cannabis use levels, yet may soon follow other jurisdictions and implement legalization of non-medical cannabis use and supply towards public health objectives. While existing cannabis-oriented interventions mainly focus on primary prevention and treatment (e.g., for dependence), key harms from use are crucially influenced by risk factors that can be modified by the user. On this basis, and similar to other health behavior-oriented interventions, ‘Lower-Risk Cannabis Use Guidelines’ (LRCUG), consisting of 10 recommendation clusters for lower-risk use, were systematically developed in Canada as an evidence-based, targeted prevention tool towards reducing adverse outcomes among cannabis users. We briefly summarize the concept of and experiences with implementation of the LRCUG elsewhere, and describe how their adoption as a population health intervention may serve public health goals of possible cannabis legalization in New Zealand and elsewhere.
Details
- Title
- The Lower-Risk Cannabis Use Guidelines (LRCUG): A ready-made targeted prevention tool for cannabis in New Zealand
- Authors
- Benedikt Fischer (Corresponding Author) - University of AucklandDimitri Daldegan-Bueno - University of AucklandRoss Bell - New Zealand Drug Foundation (New Zealand)Joseph M. Boden - University of OtagoChris Bullen - University of AucklandMichael Farrell - UNSW SydneyWayne Hall - The University of QueenslandDavid Newcombe - University of Auckland
- Publication details
- Public Health in Practice, Vol.1, pp.1-4
- Publisher
- Elsevier BV
- Date published
- 2020
- DOI
- 10.1016/j.puhip.2020.100046
- ISSN
- 2666-5352
- PMID
- 36101675
- Copyright note
- © 2020 The Author(s). Published by Elsevier Ltd on behalf of The Royal Society for Public Health. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
- Grant note
- Dr. Fischer acknowledges support from the Hugh Green Foundation Chair in Addiction Research, Faculty of Medical & Health Sciences, University of Auckland; he furthermore reports grants and contract funding on cannabis-related topics from public only (e.g., public funding, government) agencies. Dr. Farrell directs the National Drug & Alcohol Research Centre, funded by the Australian Federal Government Department of Health, and has received unrestricted research funding from Indivior, Sequeris and Mundipharma and the Therapeutic Goods Authority in Australia to assess the effectiveness of medicinal cannabinoids and to develop clinical guidance. Dr. Newcombe has received grant funding from the New Zealand Health Promotion Agency, a public agency partially funded by the levy on alcohol produced or sold in New Zealand. Other authors report no related competing interests.
- Organisation Unit
- School of Health - Psychology
- Language
- English
- Record Identifier
- 991196150802621
- Output Type
- Journal article
Metrics
1 Record Views